Search hospitals
>
Iowa
>
Des Moines
Medical Oncology and Hematology Associates-Des Moines
Claim this profile
Des Moines, Iowa 50309
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
Conducts research for Breast cancer
323 reported clinical trials
2 medical researchers
Summary
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer, Breast cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 427 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.
Area of expertise
Breast Cancer
Medical Oncology and Hematology Associates-Des Moines has run 48 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Medical Oncology and Hematology Associates-Des Moines has run 45 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Joshua Lukenbill
Medical Oncology and Hematology Associates-Des Moines
3 years of reported clinical research
Robert J. Behrens
Iowa Methodist Medical Center
5 years of reported clinical research
Clinical Trials running at Medical Oncology and Hematology Associates-Des Moines
Lung Cancer
Cancer
Prostate Cancer
Bladder Cancer
Ovarian Cancer
Breast Cancer
Melanoma
Esophageal cancer
Breast cancer
Colorectal Cancer
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting
2 awards
Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Medical Oncology and Hematology Associates-Des Moines?
Medical Oncology and Hematology Associates-Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer, Breast cancer and other specialties. Medical Oncology and Hematology Associates-Des Moines is involved with conducting 323 clinical trials across 427 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.
Where is Medical Oncology and Hematology Associates-Des Moines located?
Medical Oncology and Hematology Associates-Des Moines is situated at 1221 Pleasant St, Suite 100, Des Moines, IA 50309, conveniently located near the center of Des Moines.
Who should I call to ask about financial aid or insurance network?
At Medical Oncology and Hematology Associates, patients have access to financial counselors during their initial visits and whenever they have inquiries about their account or insurance coverage. These counselors are insurance experts ready to answer questions and confirm that a coverage plan is in place before treatment starts. They can also provide information on patient assistance programs and payment options.
What insurance does Medical Oncology and Hematology Associates-Des Moines accept?
Medical Oncology & Hematology Associates in Des Moines, IA, accepts all insurance plans. Patients must have an updated insurance card on file. Copayments, deductibles, and coinsurance are due at each visit, with any charges not covered by insurance being the responsibility of the patient or guarantor.
What awards or recognition has Medical Oncology and Hematology Associates-Des Moines received?
Medical Oncology and Hematology Associates-Des Moines, located in Des Moines, Iowa, is celebrated for its contributions to cancer research and patient care. The hospital has been actively involved in clinical trials with prestigious research groups, including the Mayo Clinic Cancer Center’s North Central Cancer Treatment Group, Eastern Cooperative Oncology Group, Southwest Oncology Group, and National Surgical Adjuvant Breast and Bowel Project. It has also been at the forefront of adjuvant therapies for colon and rectal cancers for over twenty years and registered the first patient for a clinical trial under Vice President Joe Biden’s Cancer Moonshot initiative.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.